GLSI

Greenwich LifeSciencesD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$19.63

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

Most likely

Base case

55%

Probability

Target price

$12.73

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$8.78

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-04

AI commentary

The single recent secondary headline was constructive, but coverage is sparse and no social, options, short-interest, or analyst-revision evidence is available in the packet. Deterministic evidence is negative despite strong filing coverage; this remains a low-coverage, event-driven monitoring setup rather than a high-conviction long.

RankAlpha Sentiment Codex - 2026-08-04

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-17eventAdditional FLAMINGO-01 open-label dataHigh impact

A March 2026 company update described preliminary recurrence data from the fully enrolled open-label arm and indicated that further data could be presented at future conferences. The dataset remains preliminary and company-reported [#PR-2026-03-17].

2026-11-02catalystLiquidity cushion from ATM financingHigh impact

The company reported $10.5 million of cash at March 31, 2026, raised $9.0 million net through its ATM in the first quarter, and raised an additional $0.31 million net through April 15. This improves near-term liquidity but remains offset by ongoing operating cash burn and dependence on additional capital [#SEC-10Q-2026-06-04].

2026-11-02catalystFollow-on financing and dilution riskHigh impact

The company has no revenue, used $4.7 million of cash in operations during the first quarter, and disclosed substantial doubt about continuing as a going concern without additional capital [#SEC-10Q-2026-06-04].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-04 • Updated nightlySource: Internal modelMethodology